CV Protection in the EMPA-REG OUTCOME Trial: A “Thrifty Substrate” Hypothesis
The DOI matches its Crossref record; 77 of the 77 references it cites were found in a registry or an index.
Abstract
The striking and unexpected relative risk reductions in cardiovascular (CV) mortality (38%), hospitalization for heart failure (35%), and death from any cause (32%) observed in the EMPA-REG OUTCOME trial using an inhibitor of sodium–glucose cotransporter 2 (SGLT2) in patients with type 2 diabetes and high CV risk have raised the possibility that mechanisms other than those observed in the trial—modest improvement in glycemic control, small decrease in body weight, and persistent reductions in blood pressure and uric acid level—may be at play. We hypothesize that under conditions of mild, persistent hyperketonemia, such as those that prevail during treatment with SGLT2 inhibitors, β-hydroxybutyrate is freely taken up by the heart (among other organs) and oxidized in preference to fatty acids. This fuel selection improves the transduction of oxygen consumption into work efficiency at the mitochondrial level. In addition, the hemoconcentration that typically follows SGLT2 inhibition enhances oxygen release to the tissues, thereby establishing a powerful synergy with the metabolic substrate shift. These mechanisms would cooperate with other SGLT2 inhibition–induced changes (chiefly, enhanced diuresis and reduced blood pressure) to achieve the degree of cardioprotection revealed in the EMPA-REG OUTCOME trial. This hypothesis opens up new lines of investigation into the pathogenesis and treatment of diabetic and nondiabetic heart disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., Chioncel, O., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab670 · Cited by 19,442
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
How mitochondria produce reactive oxygen species
Murphy, M. P. (2009) · Biochemical Journal · doi:10.1042/bj20081386 · Cited by 8,207 · cited 1×
“Furthermore, a persistently elevated rate of FFA oxidation generates reactive oxygen species in excess of scavenging capacity (42); the resulting oxidative stress contributes to mitochondrial damage in a range of pathologies (43).”
BackgroundESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012
Authors/Task Force Members, McMurray, J. J. V., Adamopoulos, S., Anker, S. D., Auricchio, A., Böhm, M., Dickstein, K., Falk, V., Filippatos, G., Fonseca, C., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs104 · Cited by 6,879
Eplerenone in patients with systolic heart failure and mild symptoms
Zannad, F., McMurray, J. J. V., Krum, H., van Veldhuisen, D. J., Swedberg, K., Shi, H., Vincent, J., Pocock, S. J., & Pitt, B. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009492 · Cited by 3,111
Ischaemic accumulation of succinate controls reperfusion injury through mitochondrial ROS
Chouchani, E. T., Pell, V. R., Gaude, E., Aksentijević, D., Sundier, S. Y., Robb, E. L., Logan, A., Nadtochiy, S. M., Ord, E. N. J., Smith, A. C., et al. (2014) · Nature · doi:10.1038/nature13909 · Cited by 2,907 · cited 1×
“perfusion injury (53)dconverge on insufficient mitochondrial energy output and contractile failure as the basic mechanism.”
BackgroundESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012
Authors/Task Force Members, McMurray, J. J. V., Adamopoulos, S., Anker, S. D., Auricchio, A., Böhm, M., Dickstein, K., Falk, V., Filippatos, G., Fonseca, C., et al. (2012) · European Journal of Heart Failure · doi:10.1093/eurjhf/hfs105 · Cited by 2,644
The Failing Heart — An Engine Out of Fuel
Neubauer, S. (2007) · New England Journal of Medicine · doi:10.1056/nejmra063052 · Cited by 2,417
Myocardial Fatty Acid Metabolism in Health and Disease
Lopaschuk, G. D., Ussher, J. R., Folmes, C. D. L., Jaswal, J. S., & Stanley, W. C. (2010) · Physiological Reviews · doi:10.1152/physrev.00015.2009 · Cited by 2,179
Myocardial Substrate Metabolism in the Normal and Failing Heart
Stanley, W. C., Recchia, F. A., & Lopaschuk, G. D. (2005) · Physiological Reviews · doi:10.1152/physrev.00006.2004 · Cited by 2,048 · cited 1×
“and functional manifestation (reduced or preserved ejection fraction) (51).”
Background(2013) · European Heart Journal · doi:10.1093/eurheartj/eht108 · Cited by 1,955
Suppression of Oxidative Stress by β-Hydroxybutyrate, an Endogenous Histone Deacetylase Inhibitor
Shimazu, T., Hirschey, M. D., Newman, J., He, W., Shirakawa, K., Le Moan, N., Grueter, C. A., Lim, H., Saunders, L. R., Stevens, R. D., et al. (2013) · Science · doi:10.1126/science.1227166 · Cited by 1,777
The cellular production of hydrogen peroxide
Boveris, A., Oshino, N., & Chance, B. (1972) · Biochemical Journal · doi:10.1042/bj1280617 · Cited by 1,547 · cited 1×
“Furthermore, a persistently elevated rate of FFA oxidation generates reactive oxygen species in excess of scavenging capacity (42); the resulting oxidative stress contributes to mitochondrial damage in a range of pathologies (43).”
BackgroundRegulation of hepatic fatty acid oxidation and ketone body production
McGarry, J. D., & Foster, D. W. (1980) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.49.070180.002143 · Cited by 1,460 · cited 1×
“(FFAs) to the liver stimulates ketogenesis (25), resulting in a metabolic condition resembling a prolonged fast (26).”
BackgroundCherney, D. Z. I., Perkins, B. A., Soleymanlou, N., Maione, M., Lai, V., Lee, A., Fagan, N. M., Woerle, H. J., Johansen, O. E., Broedl, U. C., et al. (2014) · Circulation · doi:10.1161/circulationaha.113.005081 · Cited by 1,329
Cahill, G. F. (2006) · Annual Review of Nutrition · doi:10.1146/annurev.nutr.26.061505.111258 · Cited by 1,319
Intensive glucose control and macrovascular outcomes in type 2 diabetes
Turnbull, F. M., Abraira, C., Anderson, R. J., Byington, R. P., Chalmers, J. P., Duckworth, W. C., Evans, G. W., Gerstein, H. C., Holman, R. R., Moritz, T. E., et al. (2009) · Diabetologia · doi:10.1007/s00125-009-1470-0 · Cited by 1,189
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients
Ferrannini, E., Muscelli, E., Frascerra, S., Baldi, S., Mari, A., Heise, T., Broedl, U. C., & Woerle, H.-J. (2014) · Journal of Clinical Investigation · doi:10.1172/jci72227 · Cited by 1,134 · cited 2×
“The subtraction of large amounts of glucose from the glucose pool, coupled with the dual hormonal changes, results in a 25% restriction of glucose utilization, and a concomitant increase in lipid mobilization and usage for energy production (24).”
BackgroundSelf-citationPsaty, B. M., Lumley, T., Furberg, C. D., Schellenbaum, G., Pahor, M., Alderman, M. H., & Weiss, N. S. (2003) · JAMA · doi:10.1001/jama.289.19.2534 · Cited by 1,088
Fitchett, D., Zinman, B., Wanner, C., Lachin, J. M., Hantel, S., Salsali, A., Johansen, O. E., Woerle, H. J., Broedl, U. C., & Inzucchi, S. E. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehv728 · Cited by 907
Blood Pressure Lowering in Type 2 Diabetes: A Systematic Review and Meta-analysis
Emdin, C. A., Rahimi, K., Neal, B., Callender, T., Perkovic, V., & Patel, A. (2015) · JAMA · doi:10.1001/jama.2014.18574 · Cited by 854
Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes
Lambers Heerspink, H. J., de Zeeuw, D., Wie, L., Leslie, B., & List, J. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12127 · Cited by 837 · cited 2×
“who were receiving treatment with dapagliflozin (19) have shown that red blood cell mass (as measured by (51)Cr-”
BackgroundMethodVeech, R. L. (2004) · Prostaglandins, Leukotrienes and Essential Fatty Acids · doi:10.1016/j.plefa.2003.09.007 · Cited by 755
Ferrannini, E., Baldi, S., Frascerra, S., Astiarraga, B., Heise, T., Bizzotto, R., Mari, A., Pieber, T. R., & Muscelli, E. (2016) · Diabetes · doi:10.2337/db15-1356 · Cited by 712
Self-citationThe Failing Heart Relies on Ketone Bodies as a Fuel
Aubert, G., Martin, O. J., Horton, J. L., Lai, L., Vega, R. B., Leone, T. C., Koves, T., Gardell, S. J., Krüger, M., Hoppel, C. L., et al. (2016) · Circulation · doi:10.1161/circulationaha.115.017355 · Cited by 707 · cited 1×
“, b-hydroxybutyrate dehydrogenase) are increased (56).”
Testani, J. M., Chen, J., McCauley, B. D., Kimmel, S. E., & Shannon, R. P. (2010) · Circulation · doi:10.1161/circulationaha.109.933275 · Cited by 680 · cited 1×
“same blood flow is expected to deliver more oxygen to tissues (62).”
BackgroundRosenstock, J., & Ferrannini, E. (2015) · Diabetes Care · doi:10.2337/dc15-1380 · Cited by 664 · cited 1×
“In patients with type 1 diabetes or insulin-treated patients with T2D who are receiving therapy with SGLT2 inhibitors, inappropriate reductions in exogenous insulin administration or intercurrent illness may precipitate episodes of nonhyperglycemic ketoacidosis (72).”
BackgroundSelf-citationBedi, K. C., Snyder, N. W., Brandimarto, J., Aziz, M., Mesaros, C., Worth, A. J., Wang, L. L., Javaheri, A., Blair, I. A., Margulies, K. B., et al. (2016) · Circulation · doi:10.1161/circulationaha.115.017545 · Cited by 650
Insulin, ketone bodies, and mitochondrial energy transduction
Sato, K., Kashiwaya, Y., Keon, C. A., Tsuchiya, N., King, M. T., Radda, G. K., Chance, B., Clarke, K., & Veech, R. L. (1995) · The FASEB Journal · doi:10.1096/fasebj.9.8.7768357 · Cited by 454 · cited 1×
“oxygen cost of this energy output to be 27% decreased (41).”
BackgroundKetone body metabolism and cardiovascular disease
Cotter, D. G., Schugar, R. C., & Crawford, P. A. (2013) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00646.2012 · Cited by 440 · cited 1×
“Finally, ketone bodies have been shown to upregulate mitochondrial biogenesis and, by stabilizing cell membrane potential, to exhibit antiarrhythmic potential (45).”
BackgroundKetone Bodies, Potential Therapeutic Uses
Veech, R. L., Chance, B., Kashiwaya, Y., Lardy, H. A., & Cahill, G. F. (2001) · IUBMB Life · doi:10.1080/152165401753311780 · Cited by 429
Atkins and other low-carbohydrate diets: hoax or an effective tool for weight loss?
Astrup, A., Larsen, T. M., & Harper, A. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16986-9 · Cited by 421 · cited 1×
“Low-carbohydrate ketogenic diets are still widely used, mainly for weight loss, but their long-term impact on CV function is still uncertain and controversial (71).”
BackgroundSGLT-2 inhibitors and cardiovascular risk: Proposed pathways and review of ongoing outcome trials
Inzucchi, S. E., Zinman, B., Wanner, C., Ferrari, R., Fitchett, D., Hantel, S., Espadero, R.-M., Woerle, H.-J., Broedl, U. C., & Johansen, O. E. (2015) · Diabetes and Vascular Disease Research · doi:10.1177/1479164114559852 · Cited by 399
Komoroski, B., Vachharajani, N., Feng, Y., Li, L., Kornhauser, D., & Pfister, M. (2009) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2008.250 · Cited by 396 · cited 1×
“action, SGLT2 inhibitors induce natriuresis and osmotic diuresis (13,14) and a drop in systolic and diastolic blood pressure levels (2); indeed, these effects have been hypothesized to play a pivotal role in”
BackgroundKetone body production and disposal: Effects of fasting, diabetes, and exercise
Balasse, E. O., & Féry, F. (1989) · Diabetes/Metabolism Reviews · doi:10.1002/dmr.5610050304 · Cited by 313 · cited 1×
“porter, which also transports pyruvate) in proportion to its plasma concentration into most organs, including heart, brain, and kidney, by a saturable transportmechanism (33).”
BackgroundDoehner, W., Rauchhaus, M., Ponikowski, P., Godsland, I. F., von Haehling, S., Okonko, D. O., Leyva, F., Proudler, A. J., Coats, A. J. S., & Anker, S. D. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.02.093 · Cited by 294 · cited 1×
“Furthermore, there is evidence that myocardial insulin resistance is an independent risk factor for mortality in stable patients with chronic heart failure (74).”
BackgroundCamici, P., Ferrannini, E., & Opie, L. H. (1989) · Progress in Cardiovascular Diseases · doi:10.1016/0033-0620(89)90027-3 · Cited by 275 · cited 1×
“the oxidation of fatty substrates (49).”
Self-citationImpact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes
Ferrannini, E., & DeFronzo, R. A. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv239 · Cited by 258
Self-citationCahill, G. F., & Veech, R. L. (2003) · PubMed · Cited by 246
Metabolic Impairment in Heart Failure
Doehner, W., Frenneaux, M., & Anker, S. D. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.04.083 · Cited by 236
Garland, P., Newsholme, E., & Randle, P. (1964) · Biochemical Journal · doi:10.1042/bj0930665 · Cited by 225
Sodium–Glucose Cotransporter Inhibitors: Effects on Renal and Intestinal Glucose Transport
Mudaliar, S., Polidori, D., Zambrowicz, B., & Henry, R. R. (2015) · Diabetes Care · doi:10.2337/dc15-0642 · Cited by 225
Camici, P. G., Marraccini, P., Lorenzoni, R., Buzzigoli, G., Pecori, N., Perissinotto, A., Ferrannini, E., L'Abbate, A., & Marzilli, M. (1991) · Journal of the American College of Cardiology · doi:10.1016/0735-1097(91)90632-j · Cited by 214 · cited 1×
“3), the fractional extraction of b-hydroxybutyrate remains highat;40%, thereby continuing to support external cardiac work (37).”
BackgroundSelf-citationDevenny, J. J., Godonis, H. E., Harvey, S. J., Rooney, S., Cullen, M. J., & Pelleymounter, M. A. (2012) · Obesity · doi:10.1038/oby.2012.59 · Cited by 212 · cited 1×
“In diet-induced obese rats treated with dapagliflozin (21), ipragliflozin (22), or tofogliflozin (23), lipolysis is accelerated and circulating ketone body levels are increased, especially in the fasting state or when animals are fed in pairs.”
BackgroundYokono, M., Takasu, T., Hayashizaki, Y., Mitsuoka, K., Kihara, R., Muramatsu, Y., Miyoshi, S., Tahara, A., Kurosaki, E., Li, Q., et al. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.01.040 · Cited by 195 · cited 1×
“In diet-induced obese rats treated with dapagliflozin (21), ipragliflozin (22), or tofogliflozin (23), lipolysis is accelerated and circulating ketone body levels are increased, especially in the fasting state or when animals are fed in pairs.”
BackgroundPathophysiology and clinical evaluation of acute heart failure
Mentz, R. J., & O'Connor, C. M. (2016) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2015.134 · Cited by 184
van der Meer, P., Postmus, D., Ponikowski, P., Cleland, J. G., O'Connor, C. M., Cotter, G., Metra, M., Davison, B. A., Givertz, M. M., Mansoor, G. A., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.12.050 · Cited by 177
Diuretics: A Review and Update
Roush, G. C., Kaur, R., & Ernst, M. E. (2014) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248413497257 · Cited by 164 · cited 1×
“trial the observed increase in hematocrit persisted for the entire duration of the trial (20).”
BackgroundIozzo, P., Chareonthaitawee, P., Dutka, D., Betteridge, D. J., Ferrannini, E., & Camici, P. G. (2002) · Diabetes · doi:10.2337/diabetes.51.10.3020 · Cited by 160
Self-citationPaternostro, G., Camici, P. G., Lammerstma, A. A., Marinho, N., Baliga, R. R., Kooner, J. S., Radda, G. K., & Ferrannini, E. (1996) · Journal of Clinical Investigation · doi:10.1172/jci119015 · Cited by 150 · cited 1×
“However, in patients with T2D (27,46) as well as in patients without diabetes with coronary artery disease (47) or stress-induced ischemia (48), whole-body and myocardial insulin-mediated glucose utilization are impaired (i.”
BackgroundSelf-citationGreene, S. J., Gheorghiade, M., Vaduganathan, M., Ambrosy, A. P., Mentz, R. J., Subacius, H., Maggioni, A. P., Nodari, S., Konstam, M. A., Butler, J., et al. (2013) · European Journal of Heart Failure · doi:10.1093/eurjhf/hft110 · Cited by 140
Effects of Insulin on Hemodynamics and Metabolism in Human Forearm
Natali, A., Buzzigoli, G., Taddei, S., Santoro, D., Cerri, M., Pedrinelli, R., & Ferrannini, E. (1990) · Diabetes · doi:10.2337/diab.39.4.490 · Cited by 139
Self-citationOlde Engberink, R. H. G., Frenkel, W. J., van den Bogaard, B., Brewster, L. M., Vogt, L., & van den Born, B.-J. H. (2015) · Hypertension · doi:10.1161/hypertensionaha.114.05122 · Cited by 134 · cited 1×
“Likewise, in systematic meta-analyses (16,17), diuretic agents appear to be associated with a smaller (;20%) reduction in CV mortality than that seen in the EMPAREG OUTCOME trial and a clear risk reduction in stroke, which was not observed in the EMPA-REG OUTCOME trial.”
BackgroundInagaki, N., Kondo, K., Yoshinari, T., Takahashi, N., Susuta, Y., & Kuki, H. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.935764 · Cited by 123 · cited 1×
“(32), plasma ketones rose dose dependently with the administration of 100 or”
BackgroundMetabolic and hemodynamic effects of insulin on human hearts
Ferrannini, E., Santoro, D., Bonadonna, R., Natali, A., Parodi, O., & Camici, P. G. (1993) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1993.264.2.e308 · Cited by 120 · cited 1×
“body tissues and with a fractional extraction (;40%) comparable to that of pyruvate and far higher than that of glucose (;2%) or FFA (15–20%) (36) (Fig.”
BackgroundSelf-citationNishimura, R., Tanaka, Y., Koiwai, K., Inoue, K., Hach, T., Salsali, A., Lund, S. S., & Broedl, U. C. (2015) · Cardiovascular Diabetology · doi:10.1186/s12933-014-0169-9 · Cited by 106
Suzuki, M., Takeda, M., Kito, A., Fukazawa, M., Yata, T., Yamamoto, M., Nagata, T., Fukuzawa, T., Yamane, M., Honda, K., et al. (2014) · Nutrition & Diabetes · doi:10.1038/nutd.2014.20 · Cited by 97
Du, Z., Shen, A., Huang, Y., Su, L., Lai, W., Wang, P., Xie, Z., Xie, Z., Zeng, Q., Ren, H., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0088102 · Cited by 96 · cited 1×
“Thus, the failing heart attempts to cope with the increased energy expenditure (59) by turning to ketone use at the expense of fatty acid use (60).”
BackgroundSubstrate Signaling by Insulin
Kashiwaya, Y., King, M. T., & Veech, R. L. (1997) · The American Journal of Cardiology · doi:10.1016/s0002-9149(97)00458-x · Cited by 86 · cited 1×
“In perfused working rat hearts, bhydroxybutyrate supplementation inhibits pyruvate oxidation by deactivating pyruvate dehydrogenase (38), mimics insulin action (39), and competes with oxidation of FFAs (possibly also by impeding”
BackgroundStanley, W. C., Meadows, S. R., Kivilo, K. M., Roth, B. A., & Lopaschuk, G. D. (2003) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00332.2003 · Cited by 83
EMPA-REG – the “diuretic hypothesis”
McMurray, J. J. V. (2015) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2015.10.012 · Cited by 83 · cited 1×
“the CV benefit shown by the EMPA-REG OUTCOME trial (10,11), especially during the early weeks of treatment when the systolic blood pressure gradient between”
MethodAltered systemic ketone body metabolism in advanced heart failure.
Janardhan, A. H., Chen, J., & Crawford, P. A. (2011) · Europe PMC (PubMed Central) · Cited by 79
Understanding EMPA-REG OUTCOME
Muskiet, M. H. A., van Raalte, D. H., van Bommel, E. J. M., Smits, M. M., & Tonneijck, L. (2015) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00424-6 · Cited by 79
Ikeda, S., Takano, Y., Cynshi, O., Tanaka, R., Christ, A. D., Boerlin, V., Beyer, U., Beck, A., Ciorciaro, C., Meyer, M., et al. (2015) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12538 · Cited by 73
Ketones Step to the Plate: A Game Changer for Metabolic Remodeling in Heart Failure?
Kolwicz, S. C., Airhart, S., & Tian, R. (2016) · Circulation · doi:10.1161/circulationaha.116.021230 · Cited by 68
Therapeutic potential of pyruvate therapy for mitochondrial diseases
Tanaka, M., Nishigaki, Y., Fuku, N., Ibi, T., Sahashi, K., & Koga, Y. (2007) · Mitochondrion · doi:10.1016/j.mito.2007.07.002 · Cited by 60
Iozzo, P., Chareonthaitawee, P., Rimoldi, O. E., Betteridge, D. J., Camici, P. G., & Ferrannini, E. (2002) · Diabetologia · doi:10.1007/s00125-002-0917-3 · Cited by 51
Self-citationNishimura, R., Osonoi, T., Kanada, S., Jinnouchi, H., Sugio, K., Omiya, H., Ubukata, M., Sakai, S., & Samukawa, Y. (2015) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12481 · Cited by 49
The EMPA-REG study: What has it told us? A diabetologist’s perspective
DeFronzo, R. A. (2015) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2015.10.013 · Cited by 44 · cited 1×
“the CV benefit shown by the EMPA-REG OUTCOME trial (10,11), especially during the early weeks of treatment when the systolic blood pressure gradient between”
MethodFujii, T., Nozaki, F., Saito, K., Hayashi, A., Nishigaki, Y., Murayama, K., Tanaka, M., Koga, Y., Hiejima, I., & Kumada, T. (2014) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2014.04.008 · Cited by 41 · cited 1×
“In this context, b-hydroxybutyrate can be viewed as a constitutive mitochondrial helper, just as is its closest kin of energetics, pyruvate (54,55) (Table 1).”
BackgroundMetabolic markers of stress-induced myocardial ischemia.
Camici, P. G., Marraccini, P., Lorenzoni, R., Ferrannini, E., Buzzigoli, G., Marzilli, M., & L’Abbate, A. (1991) · PubMed · Cited by 32
Self-citationUnderstanding EMPA-REG OUTCOME
Ceriello, A., Genovese, S., Mannucci, E., & Gronda, E. (2015) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00426-x · Cited by 31
Martini, J., Tsai, A. G., Cabrales, P., Johnson, P. C., & Intaglietta, M. (2006) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.01218.2005 · Cited by 30
Nishimura, R., Omiya, H., Sugio, K., Ubukata, M., Sakai, S., & Samukawa, Y. (2015) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12611 · Cited by 26
Failure of Hyperketonemia to Alter Basal and Insulin-Mediated Glucose Metabolism in Man
Bratusch-Marrain, P. R., & DeFronzo, R. A. (1986) · Hormone and Metabolic Research · doi:10.1055/s-2007-1012266 · Cited by 16
Understanding EMPA-REG OUTCOME
Gilbert, R. E., & Connelly, K. A. (2015) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00427-1 · Cited by 12
Anemia Management in Heart Failure: A Thick Review of Thin Data
McBride, B. F., & White, C. M. (2004) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.24.8.757.36072 · Cited by 9 · cited 1×
“In quantitative terms, experiments in hamsters transfused with packed red blood cells (63) demonstrate that short-term increments in the hematocrit (up to ;10%) induce a 20% rise in oxygen delivery to tissues, coupled with a 10% drop in arterial blood pressure and an increase in cardiac output.”
Background
Cited by
Diabetes, Hypertension, and Cardiovascular Disease: Clinical Insights and Vascular Mechanisms
Petrie, J. R., Guzik, T. J., & Touyz, R. M. (2018) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2017.12.005 · Cited by 1,787
Multi-dimensional Roles of Ketone Bodies in Fuel Metabolism, Signaling, and Therapeutics
Puchalska, P., & Crawford, P. A. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2016.12.022 · Cited by 1,610
“Inhibition of the renal proximal tubular sodium/glucose cotransporter 2 (SGLT2i) increases circulating ketone body concentrations in humans (Ferrannini et al., 2016a; Inagaki et al., 2015) and mice (Suzuki et al., 2014) via increased hepatic ketogenesis (Ferrannini et al., 2014, 2016a; Katz and…”
BackgroundHeerspink, H. J. L., Perkins, B. A., Fitchett, D. H., Husain, M., & Cherney, D. Z. I. (2016) · Circulation · doi:10.1161/circulationaha.116.021887 · Cited by 1,376
SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review
Verma, S., & McMurray, J. J. V. (2018) · Diabetologia · doi:10.1007/s00125-018-4670-7 · Cited by 999
Mechanisms of Cardiovascular Benefits of Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors
Lopaschuk, G. D., & Verma, S. (2020) · JACC: Basic to Translational Science · doi:10.1016/j.jacbts.2020.02.004 · Cited by 894
Metadata
- Authors
- Ferrannini, E., Mark, M., & Mayoux, E.
- Affiliations
- Istituto di Fisiologia Clinica (IT)
- Boehringer Ingelheim (Germany) (DE)
- Corresponding author
- Ferrannini, Ele
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2016-06-11
- Volume
- 39
- Issue
- 7
- Pages
- 1108-1114
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2412800896
- Cited by
- 975
- References
- 77
- Citations by year
- 2026: 53 · 2025: 53 · 2024: 73 · 2023: 79 · 2022: 91 · 2021: 134 · 2020: 114 · 2019: 100 · 2018: 110 · 2017: 119 · 2016: 47
- FWCI
- 125.98
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Keywords
- SGLT2 inhibitors, EMPA-REG OUTCOME trial, cardioprotection, type 2 diabetes, hyperketonemia, beta-hydroxybutyrate, mitochondrial oxygen consumption, hemoconcentration, heart failure, cardiovascular mortality, diabetic heart disease
- MeSH terms
- Sodium-Glucose Transporter 2 Inhibitors, Benzhydryl Compounds, Blood Glucose, Blood Pressure, Cardiovascular Diseases, Clinical Trials as Topic, Diabetes Mellitus, Type 2, Diabetic Angiopathies, Glucosides, Heart, Humans, Hypoglycemic Agents, Models, Biological, Research Design, Treatment Outcome, 3-Hydroxybutyric Acid, Sodium-Glucose Transporter 2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.